• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

需要多少个突变型p53分子才能使一个四聚体失活?

How many mutant p53 molecules are needed to inactivate a tetramer?

作者信息

Chan Wan Mui, Siu Wai Yi, Lau Anita, Poon Randy Y C

机构信息

Department of Biochemistry, Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong.

出版信息

Mol Cell Biol. 2004 Apr;24(8):3536-51. doi: 10.1128/MCB.24.8.3536-3551.2004.

DOI:10.1128/MCB.24.8.3536-3551.2004
PMID:15060172
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC381690/
Abstract

The tumor suppressor p53 is transcription factor composed of four identical subunits. The majority of the mutations in p53 are missense mutations that impair DNA binding. On the other hand, the p53-related p63 and p73 genes are rarely mutated, but many cell types express natural variants lacking the N-terminal transactivation domain (NDelta). Compelling evidence indicates that both the DNA binding-defective and NDelta mutants can impair the function of wild-type p53 in a dominant-negative manner. Interestingly, it is uncertain how many mutant subunit(s) a p53 tetramer can tolerate. In this study, we first made theoretical predictions based on the number of mutant p53 monomers needed to inactivate a tetramer and then tested how well the experimental data fit the predicted values. Surprisingly, these experiments reveal that DNA binding-defective p53 mutants (R249S and R273H) are very ineffective in impairing the transcriptional activity of p53: at least three mutants are required to inactivate a tetramer. In marked contrast, p53NDelta is a very potent inhibitor of p53: one NDelta subunit per tetramer is sufficient to abolish the transcriptional activity. DNA binding is not necessary for the NDelta proteins to inactivate p53. Similarly, NDelta variants of p63 and p73 are also powerful inhibitors of members of the p53 family. These results have important implications for our thinking about the mechanism of tumorigenesis involving missense p53 mutants or the N-terminally truncated isoforms.

摘要

肿瘤抑制因子p53是一种由四个相同亚基组成的转录因子。p53中的大多数突变是损害DNA结合的错义突变。另一方面,与p53相关的p63和p73基因很少发生突变,但许多细胞类型表达缺乏N端反式激活结构域(NDelta)的天然变体。有力证据表明,DNA结合缺陷型和NDelta突变体都能以显性负性方式损害野生型p53的功能。有趣的是,尚不确定一个p53四聚体能够耐受多少个突变亚基。在本研究中,我们首先根据使一个四聚体失活所需的突变p53单体数量进行理论预测,然后测试实验数据与预测值的拟合程度。令人惊讶的是,这些实验表明,DNA结合缺陷型p53突变体(R249S和R273H)在损害p53的转录活性方面非常低效:至少需要三个突变体才能使一个四聚体失活。与之形成鲜明对比的是,p53NDelta是p53的一种非常有效的抑制剂:每个四聚体一个NDelta亚基就足以消除转录活性。NDelta蛋白使p53失活并不需要DNA结合。同样,p63和p73的NDelta变体也是p53家族成员的强大抑制剂。这些结果对于我们思考涉及错义p53突变体或N端截短异构体的肿瘤发生机制具有重要意义。

相似文献

1
How many mutant p53 molecules are needed to inactivate a tetramer?需要多少个突变型p53分子才能使一个四聚体失活?
Mol Cell Biol. 2004 Apr;24(8):3536-51. doi: 10.1128/MCB.24.8.3536-3551.2004.
2
Functional interplay between MDM2, p63/p73 and mutant p53.MDM2、p63/p73与突变型p53之间的功能相互作用。
Oncogene. 2015 Aug 13;34(33):4300-10. doi: 10.1038/onc.2014.359. Epub 2014 Nov 24.
3
p21/CDKN1A mediates negative regulation of transcription by p53.p21/CDKN1A介导p53对转录的负调控。
J Biol Chem. 2003 Aug 29;278(35):32507-16. doi: 10.1074/jbc.M212517200. Epub 2003 May 13.
4
Functional inactivation of p73, a homolog of p53 tumor suppressor protein, by human papillomavirus E6 proteins.人乳头瘤病毒E6蛋白导致p53肿瘤抑制蛋白的同源物p73功能失活。
Int J Cancer. 2001 Mar 15;91(6):822-7. doi: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1130>3.0.co;2-0.
5
A possible role of p73 on the modulation of p53 level through MDM2.p73 通过 MDM2 对 p53 水平进行调节的一种可能作用。
Cancer Res. 2001 Feb 15;61(4):1598-603.
6
Tumor-derived mutations within the DNA-binding domain of p53 that phenotypically resemble the deletion of the proline-rich domain.p53 蛋白 DNA 结合结构域内源自肿瘤的突变,其表型类似于富含脯氨酸结构域的缺失。
Oncogene. 2000 Mar 30;19(14):1834-42. doi: 10.1038/sj.onc.1203500.
7
A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain.肿瘤来源的p53突变形式的一个子集通过与p53核心结构域直接相互作用下调p63和p73。
Mol Cell Biol. 2001 Mar;21(5):1874-87. doi: 10.1128/MCB.21.5.1874-1887.2001.
8
Resistance of mitochondrial p53 to dominant inhibition.线粒体p53对显性抑制的抗性。
Mol Cancer. 2008 Jun 12;7:54. doi: 10.1186/1476-4598-7-54.
9
p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.p53突变体通常能够反式激活含有p21反应元件的启动子,但不能激活含有Bax或PIG3反应元件的启动子。
Oncogene. 2001 Jun 14;20(27):3573-9. doi: 10.1038/sj.onc.1204468.
10
The C terminus of p53 family proteins is a cell fate determinant.p53家族蛋白的C末端是细胞命运的决定因素。
Mol Cell Biol. 2005 Mar;25(5):2014-30. doi: 10.1128/MCB.25.5.2014-2030.2005.

引用本文的文献

1
Δ133p53α and Δ160p53α isoforms of the tumor suppressor protein p53 exert dominant-negative effect primarily by co-aggregation.肿瘤抑制蛋白p53的Δ133p53α和Δ160p53α亚型主要通过共聚集发挥显性负效应。
Elife. 2025 Jul 21;14:RP106469. doi: 10.7554/eLife.106469.
2
The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wild-Type p53 to Exert the Dominant-Negative Effect.p53错义变体R248Q的半衰期延长促进了其积累以及与野生型p53形成异源四聚体,从而发挥显性负效应。
Cancer Res. 2025 Jun 2;85(11):1978-1996. doi: 10.1158/0008-5472.CAN-24-1136.
3
Heterozygous TP63 pathogenic variants in isolated primary ovarian insufficiency.孤立性原发性卵巢功能不全中杂合性 TP63 致病性变异。
J Assist Reprod Genet. 2023 Sep;40(9):2211-2218. doi: 10.1007/s10815-023-02886-w. Epub 2023 Jul 15.
4
The Competition of Yin and Yang: Exploring the Role of Wild-Type and Mutant p53 in Tumor Progression.阴阳之较量:探究野生型和突变型p53在肿瘤进展中的作用
Biomedicines. 2023 Apr 17;11(4):1192. doi: 10.3390/biomedicines11041192.
5
P63 and P73 Activation in Cancers with p53 Mutation.p53 突变型癌症中的 P63 和 P73 激活
Biomedicines. 2022 Jun 23;10(7):1490. doi: 10.3390/biomedicines10071490.
6
Distinct interactors define the p63 transcriptional signature in epithelial development or cancer.不同的相互作用因子定义了上皮发育或癌症中的 p63 转录特征。
Biochem J. 2022 Jun 30;479(12):1375-1392. doi: 10.1042/BCJ20210737.
7
Mutant p53: it's not all one and the same.突变型 p53:并非千篇一律。
Cell Death Differ. 2022 May;29(5):983-987. doi: 10.1038/s41418-022-00989-y. Epub 2022 Mar 31.
8
Should mutant TP53 be targeted for cancer therapy?是否应该针对突变型 TP53 进行癌症治疗?
Cell Death Differ. 2022 May;29(5):911-920. doi: 10.1038/s41418-022-00962-9. Epub 2022 Mar 24.
9
NAMPT Inhibitor and P73 Activator Represses P53 R175H Mutated HNSCC Cell Proliferation in a Synergistic Manner.NAMPT 抑制剂和 P73 激活剂以协同方式抑制 P53 R175H 突变的头颈部鳞状细胞癌细胞增殖。
Biomolecules. 2022 Mar 12;12(3):438. doi: 10.3390/biom12030438.
10
Mutations in TP53 and PIK3CA genes in hepatocellular carcinoma patients are associated with chronic Schistosomiasis.肝细胞癌患者中TP53和PIK3CA基因的突变与慢性血吸虫病有关。
Saudi J Biol Sci. 2022 Feb;29(2):848-853. doi: 10.1016/j.sjbs.2021.10.022. Epub 2021 Oct 12.

本文引用的文献

1
DNA damage during the spindle-assembly checkpoint degrades CDC25A, inhibits cyclin-CDC2 complexes, and reverses cells to interphase.纺锤体组装检查点期间的DNA损伤会降解细胞分裂周期蛋白25A(CDC25A),抑制细胞周期蛋白-CDC2复合物,并使细胞逆转至间期。
Mol Biol Cell. 2003 Oct;14(10):3989-4002. doi: 10.1091/mbc.e03-03-0168. Epub 2003 Jul 25.
2
Germline TP53 mutations and Li-Fraumeni syndrome.种系TP53突变与李-弗劳梅尼综合征。
Hum Mutat. 2003 Mar;21(3):313-20. doi: 10.1002/humu.10185.
3
The candidate tumor suppressor ING1b can stabilize p53 by disrupting the regulation of p53 by MDM2.候选肿瘤抑制因子ING1b可通过破坏MDM2对p53的调控来稳定p53。
Cancer Res. 2002 Sep 1;62(17):4890-3.
4
Cyclin F is degraded during G2-M by mechanisms fundamentally different from other cyclins.细胞周期蛋白F在G2-M期通过与其他细胞周期蛋白根本不同的机制被降解。
J Biol Chem. 2002 Sep 20;277(38):35140-9. doi: 10.1074/jbc.M205503200. Epub 2002 Jul 16.
5
p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products.p53的稳定性和活性受Mdm2介导的替代性p53翻译产物诱导的调控。
Nat Cell Biol. 2002 Jun;4(6):462-7. doi: 10.1038/ncb801.
6
Autoinhibitory regulation of p73 by Delta Np73 to modulate cell survival and death through a p73-specific target element within the Delta Np73 promoter.Delta Np73对p73的自抑制调节,通过Delta Np73启动子内的p73特异性靶元件来调控细胞存活和死亡。
Mol Cell Biol. 2002 Apr;22(8):2575-85. doi: 10.1128/MCB.22.8.2575-2585.2002.
7
Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function.p53的靶向点突变导致野生型p53功能的显性负性抑制。
Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2948-53. doi: 10.1073/pnas.052713099. Epub 2002 Feb 26.
8
Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis.反式激活缺陷型Delta TA-p73通过直接竞争DNA结合来抑制p53:对肿瘤发生的影响。
J Biol Chem. 2002 Apr 19;277(16):14177-85. doi: 10.1074/jbc.M200480200. Epub 2002 Feb 13.
9
Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73.DeltaNp73的潜在致癌性:一种新发现的人类p73异构体
Cancer Res. 2002 Feb 1;62(3):636-41.
10
On the shoulders of giants: p63, p73 and the rise of p53.站在巨人的肩膀上:p63、p73与p53的崛起
Trends Genet. 2002 Feb;18(2):90-5. doi: 10.1016/s0168-9525(02)02595-7.